Citigroup Maintains Neutral on Arcturus Therapeutics, Raises Price Target to $8
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and raises the price target from $7 to $8.
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and raises the price target from $7 to $8.